Compare Incyte Corporation (INCY) vs JPMorgan Equity Premium Income ETF (JEPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs JPMorgan Equity Premium Income ETF — how do they compare? Incyte Corporation trades at $113.05 (market cap $22.85B), while JPMorgan Equity Premium Income ETF trades at $56.79 (market cap $45.55B). The key difference: JPMorgan Equity Premium Income ETF is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and JPMorgan Equity Premium Income ETF for 57 Days on average.
| INCY | JEPI | |
|---|---|---|
Market Cap | $22.85B | $45.55B |
Volume | 1,927,029 | 3,820,809 |
Sector | Health | Income / Options Overlay |
52-Week High | $129.93 | $59.88 |
52-Week Low | $83.80 | $55.29 |
Typical Hold Time | 33 Days | 57 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
JEPI trades at $56.79, up 0.6% with a bearish technical signal from moving averages. The ETF shows neutral momentum oscillators and key support at $56. Recent dividend activity includes three distributions averaging $0.36 per share through August-October 2026. Media coverage focuses on income generation strategies and tax implications for retirement portfolios.
The covered-call strategy provides consistent income but may limit upside during market rallies. Institutional interest remains strong with recent position increases. Key risks include interest rate sensitivity and the trade-off between yield and capital appreciation potential in rising markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →
